Related Experiment Videos
Hepatitis C virus: current understanding and prospects for future therapies
1Division of Gastroenterology and Hepatology, Portland VA Medical Center, Portland, OR 97207, USA. hugo.rosen@med.va.gov
Molecular Medicine Today
|August 27, 1999
Summary
Hepatitis C virus (HCV) infection often becomes chronic due to viral diversity, hindering immune control. Current treatments show limited success, necessitating novel antiviral strategies and better drug development models.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Hepatitis C virus (HCV) is a primary cause of chronic liver disease and liver transplantation globally.
- HCV's chronicity is linked to viral heterogeneity, enabling immune evasion.
- Interferon alpha (IFN-alpha) therapy has shown limited efficacy for HCV infection.
Purpose of the Study:
- To review the challenges and advancements in managing Hepatitis C virus infection.
- To explore novel therapeutic strategies and drug development for HCV.
- To identify predictors of treatment outcomes in HCV patients.
Main Methods:
- Molecular analysis of HCV RNA levels and genotypes before and during treatment.
- Review of current and emerging antiviral agents targeting HCV replication.
- Assessment of limitations in current HCV research models.
Main Results:
- High HCV RNA levels and genotype 1 are independent predictors of poor treatment response.
- Combination therapies and higher IFN-alpha doses may improve viral suppression.
- New antiviral agents targeting HCV enzymes and genetic approaches are under development.
Conclusions:
- HCV treatment remains challenging due to viral factors and limited therapeutic options.
- Predictive markers like viral load and genotype are crucial for treatment stratification.
- Development of effective antiviral drugs is hampered by the lack of suitable research models.